排序方式: 共有3条查询结果,搜索用时 15 毫秒
1
1.
Fatemeh Vahidian Hamed Mohammadi Mohammad Ali-Hasanzadeh Afshin Derakhshani Masoud Mostaan Maryam Hemmatzadeh Behzad Baradaran 《Journal of cellular physiology》2019,234(4):3294-3306
MicroRNAs (miRNAs) can control cancer and cancer stem cells (CSCs), and this topic has drawn immense attention recently. Stem cells are a tiny population of a bulk of tumor cells that have enormous potential in expansion and metastasis of the tumor. miRNA have a crucial role in the management of the function of stem cells. This role is to either promote or suppress the tumor. In this review, we investigated the function and different characteristics of CSCs and function of the miRNAs that are related to them. We also demonstrated the role and efficacy of these miRNAs in breast cancer and breast cancer stem cells (BCSC). Eventually, we revealed the metastasis, tumor formation, and their role in the apoptosis process. Also, the therapeutic potential of miRNA as an effective method for the treatment of BCSC was described. Extensive research is required to investigate the employment or suppression of these miRNAs for therapeutics approached in different cancers in the future. 相似文献
2.
Vahidian Fatemeh Safarzadeh Elham Mohammadi Ali Najjary Shiva Mansoori Behzad Majidi Jafar Babaloo Zohreh Aghanejad Ayoub Shadbad Mahdi Abdoli Mokhtarzadeh Ahad Baradaran Behzad 《Molecular biology reports》2020,47(12):9541-9551
Molecular Biology Reports - CD44, as a superficial cellular glycoprotein, is an essential factor in cell–cell and cell–matrix interaction. The CD44 expression level has been... 相似文献
3.
Afshin Derakhshani Zohreh Rezaei Hossein Safarpour Morteza Sabri Atefeh Mir Mohammad Amin Sanati Fatemeh Vahidian Ali Gholamiyan Moghadam Ali Aghadoukht Khalil Hajiasgharzadeh Behzad Baradaran 《Journal of cellular physiology》2020,235(4):3142-3156
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has challenged the use of this drug in the management of HER2-positive BC. Therefore, the determination of resistance mechanisms and the incorporation of new agents may lead to the development of a better blockade of the HER family receptor signaling. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab-resistant HER2-positive BC that have more effective influences in the management of this condition. In this regard, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab-resistant HER2-positive BC subjects. 相似文献
1